LncRNA CRNDE Promotes Cell Proliferation, Migration and Invasion of Ovarian Cancer Via MiR-423-5p/FSCN1 Axis

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2022 Feb 15

PMID 35166986

Authors

Qiong Wang

Ling-Xiong Wang

Chun-Yan Zhang

Nan Bai

Chen Feng

Zhuo-Mei Zhang

Liang Wang

Zhen-Zhen Gao

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer seriously threatens the health of women. LncRNA CRNDE is known to be upregulated in ovarian cancer. However, the mechanism by which CRNDE regulates the progress of ovarian cancer is largely unknown. MTT assay was applied to measure the cell viability. Colony formation assay was used to measure the cell proliferation. Cell migration was tested by wound healing, and Transwell assay was performed to detect cell invasion. In addition, the expression of miR-423-5p, CRNDE and FSCN1 were detected by RT-qPCR and western blotting, respectively. Meanwhile, dual-luciferase reporter assay and RIP assay were performed to explore the correlation between miR-423-5p and CRNDE (or FSCN1). CRNDE and FSCN1 were upregulated in ovarian cancer cells (SKOV3, CAOV-3, IGROV1, A2780 and C13K), while miR-423-5p was downregulated. Moreover, silencing of FSCN1/CRNDE significantly decreased proliferation, migration and invasion of ovarian cancer cells (SKOV3 and CI3K) via suppressing MMP-2 and MMP-9. In addition, CRNDE could sponge miR-423-5p, and FSCN1 was confirmed to be the direct target of miR-423-5p. Furthermore, CRNDE knockdown-induced inhibition of FSCN1 was notably reversed by miR-423-5p downregulation. Knockdown of CRNDE inhibited cell proliferation, migration and invasion of ovarian cancer via miR-423-5p/FSCN1 axis. Thus, CRNDE may serve a new target for ovarian cancer.

Citing Articles

Long non-coding RNA CRNDE promotes the progress of hypertrophic scar via regulating the proliferation and migration of hypertrophic scar fibroblasts through targeting microRNA-29a-3p.

Wang Z, Wu X, Zeng L Arch Dermatol Res. 2025; 317(1):440.

PMID: 39976754 DOI: 10.1007/s00403-025-03939-z.

TFAP2A-regulated CRNDE enhances colon cancer progression and chemoresistance via RIPK3 interaction.

Gao X, Huang Y, Wei T, Xue J, Iurii F, Yang L Funct Integr Genomics. 2025; 25(1):36.

PMID: 39954131 PMC: 11829933. DOI: 10.1007/s10142-025-01545-w.

Long Non-Coding RNAs in Ovarian Cancer: Mechanistic Insights and Clinical Applications.

Basu S, Nadhan R, Dhanasekaran D Cancers (Basel). 2025; 17(3).

PMID: 39941838 PMC: 11815776. DOI: 10.3390/cancers17030472.

LncRNA DNM1P35 sponges hsa-mir-326 to promote ovarian cancer progression.

Shen M, Mao Y, Wang X, Huang J, Zhang Q, Zhang J Sci Rep. 2024; 14(1):31502.

PMID: 39732940 PMC: 11682247. DOI: 10.1038/s41598-024-83170-4.

Salidroside overcomes cisplatin resistance in ovarian cancer via the inhibition of CRNDE-mediated autophagy.

Yu G, Nanding A Mol Cell Biochem. 2024; .

PMID: 39636431 DOI: 10.1007/s11010-024-05168-w.

References

Allen B, Brown J, Mountford M, Tamat S, Patwardhan A, Moore D . In vitro and in vivo studies of boron conjugated melanoma affined biochemicals. Strahlenther Onkol. 1989; 165(2-3):163-5. View

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

Karst A, Drapkin R . Ovarian cancer pathogenesis: a model in evolution. J Oncol. 2009; 2010:932371. PMC: 2739011. DOI: 10.1155/2010/932371. View

Reid B, Permuth J, Sellers T . Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017; 14(1):9-32. PMC: 5365187. DOI: 10.20892/j.issn.2095-3941.2016.0084. View

Doherty J, Peres L, Wang C, Way G, Greene C, Schildkraut J . Challenges and Opportunities in Studying the Epidemiology of Ovarian Cancer Subtypes. Curr Epidemiol Rep. 2017; 4(3):211-220. PMC: 5718213. DOI: 10.1007/s40471-017-0115-y. View

Kiesslich T, Pichler M, Neureiter D . Epigenetic control of epithelial-mesenchymal-transition in human cancer. Mol Clin Oncol. 2014; 1(1):3-11. PMC: 3956244. DOI: 10.3892/mco.2012.28. View

Meng F, Wu G . The rejuvenated scenario of epithelial-mesenchymal transition (EMT) and cancer metastasis. Cancer Metastasis Rev. 2012; 31(3-4):455-67. DOI: 10.1007/s10555-012-9379-3. View

Hashimoto Y, Skacel M, Adams J . Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker?. Int J Biochem Cell Biol. 2005; 37(9):1787-804. DOI: 10.1016/j.biocel.2005.05.004. View

Al-Alwan M, Olabi S, Ghebeh H, Barhoush E, Tulbah A, Al-Tweigeri T . Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules. PLoS One. 2011; 6(11):e27339. PMC: 3208623. DOI: 10.1371/journal.pone.0027339. View

10.

Winder S, Ayscough K . Actin-binding proteins. J Cell Sci. 2005; 118(Pt 4):651-4. DOI: 10.1242/jcs.01670. View

11.

Li J, Zhang S, Pei M, Wu L, Liu Y, Li H . FSCN1 Promotes Epithelial-Mesenchymal Transition Through Increasing Snail1 in Ovarian Cancer Cells. Cell Physiol Biochem. 2018; 49(5):1766-1777. DOI: 10.1159/000493622. View

12.

Zhang H, Zhu F, Zhu Y, Hu Y, Chen X . Effects of IL-18 on the proliferation and steroidogenesis of bovine theca cells: Possible roles in the pathogenesis of polycystic ovary syndrome. J Cell Mol Med. 2021; 25(2):1128-1139. PMC: 7812265. DOI: 10.1111/jcmm.16179. View

13.

Tang R, Wang J, Zhou M, Lan Y, Jiang L, Price M . Comprehensive analysis of lncRNA and mRNA expression changes in Tibetan chicken lung tissue between three developmental stages. Anim Genet. 2020; 51(5):731-740. DOI: 10.1111/age.12990. View

14.

Wang B, Yang B, Ling Y, Zhang J, Hua X, Gu W . Role of CD19 and specific KIT-D816 on risk stratification refinement in t(8;21) acute myeloid leukemia induced with different cytarabine intensities. Cancer Med. 2020; 10(3):1091-1102. PMC: 7897948. DOI: 10.1002/cam4.3705. View

15.

Li Y, Hou C, Dong Y, Zhu L, Xu H . Long noncoding RNA LINP1 promoted proliferation and invasion of ovarian cancer via inhibiting KLF6. Eur Rev Med Pharmacol Sci. 2020; 24(15):7918. DOI: 10.26355/eurrev_202008_22452. View

16.

He Y, Wei L, Zhang S, Liu H, Fang F, Li Y . LncRNA PLAC2 Positively Regulates CDK2 to Promote Ovarian Carcinoma Cell Proliferation. Cancer Manag Res. 2020; 12:5713-5720. PMC: 7367733. DOI: 10.2147/CMAR.S242781. View

17.

Yan H, Li H, Silva M, Guan Y, Yang L, Zhu L . LncRNA FLVCR1-AS1 mediates miR-513/YAP1 signaling to promote cell progression, migration, invasion and EMT process in ovarian cancer. J Exp Clin Cancer Res. 2019; 38(1):356. PMC: 6694549. DOI: 10.1186/s13046-019-1356-z. View

18.

You Q, Shi H, Gong C, Tian X, Li S . Long non-coding RNA DLX6-AS1 acts as an oncogene by targeting miR-613 in ovarian cancer. Eur Rev Med Pharmacol Sci. 2019; 23(15):6429-6435. DOI: 10.26355/eurrev_201908_18524. View

19.

Luo X, Tu T, Zhong Y, Xu S, Chen X, Chen L . ceRNA Network Analysis Shows That lncRNA CRNDE Promotes Progression of Glioblastoma Through Sponge mir-9-5p. Front Genet. 2021; 12:617350. PMC: 7985093. DOI: 10.3389/fgene.2021.617350. View

20.

Zhu H, Gao Y, Wang Y, Liang C, Zhang Z, Chen Y . LncRNA CRNDE promotes the progression and angiogenesis of pancreatic cancer via miR-451a/CDKN2D axis. Transl Oncol. 2021; 14(7):101088. PMC: 8081992. DOI: 10.1016/j.tranon.2021.101088. View